Refine
Year of publication
- 2009 (2) (remove)
Document Type
- Article (2)
Has Fulltext
- yes (2)
Is part of the Bibliography
- no (2)
Keywords
- Ehrung (1)
Institute
- Medizin (1)
Introduction: Reliable predictive and prognostic markers for routine diagnostic purposes are needed for breast cancer patients treated with neoadjuvant chemotherapy. We evaluated protein biomarkers in a cohort of 116 participants of the GeparDuo study on anthracycline/taxane-based neoadjuvant chemotherapy for operable breast cancer to test for associations with pathological complete response (pCR) and disease-free survival (DFS). Particularly, we evaluated if interactions between hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) expression might lead to a different clinical behavior of HR+/HER2+ coexpressing and HR+/HER2- tumors and whether subgroups of triple negative tumors might be identified by the help of Ki67 labeling index, cytokeratin 5/6 (CK5/6), as well as cyclooxygenase-2 (COX-2), and Y-box binding protein 1 (YB-1) expression. Methods: Expression analysis was performed using immunohistochemistry and silver-enhanced in situ hybridization on tissue microarrays (TMAs) of pretherapeutic core biopsies. Results: pCR rates were significantly different between the biology-based tumor types (P = 0.044) with HR+/HER2+ and HR-/HER2- tumors having higher pCR rates than HR+/HER2-tumors. Ki67 labeling index, confirmed as significant predictor of pCR in the whole cohort (P = 0.001), identified HR-/HER- (triple negative) carcinomas with a higher chance for a pCR (P = 0.006). Biology-based tumor type (P = 0.046 for HR+/HER2+vs. HR+/HER2-), Ki67 labeling index (P = 0.028), and treatment arm (P = 0.036) were independent predictors of pCR in a multivariate model. DFS was different in the biology-based tumor types (P < 0.0001) with HR+/HER2- and HR+/HER2+ tumors having the best prognosis and HR-/HER2+ tumors showing the worst outcome. Biology-based tumor type was an independent prognostic factor for DFS in multivariate analysis (P < 0.001). Conclusions: Our data demonstrate that a biology-based breast cancer classification using estrogen receptor (ER), progesterone receptor (PgR), and HER2 bears independent predictive and prognostic potential. The HR+/HER2+ coexpressing carcinomas emerged as a group of tumors with a good response rate to neoadjuvant chemotherapy and a favorable prognosis. HR+/HER2- tumors had a good prognosis irrespective of a pCR, whereas patients with HR-/HER- and HR-/HER+ tumors, especially if they had not achieved a pCR, had an unfavorable prognosis and are in need of additional treatment options. Trial registration ClinicalTrials.gov identifier: NCT00793377
Arno Kuhlig zum Gedenken
(2009)
Arno Kuhlig verstarb am 30.09.2008 im Alter von 78 Jahren in Bitterfeld. Die Nachricht von seinem Tod kam für uns alle überraschend. Arno Kuhlig wurde am 07.04.1930 in Bitterfeld geboren. Er besuchte bis 1944 die Volksschule, lernte danach Betriebsschlosser und Isolierklempner und war 25 Jahre bei einer Montagefirma tätig. Anschließend arbeitete er in seinem Beruf im damaligen Chemiekombinat Bitterfeld. Im April 1987 musste er plötzlich wegen einer schweren Krankheit aus dem Berufsleben ausscheiden. Arno Kuhlig gehörte 1949 mit zu den Gründern der heutigen „NABU Fachgruppe Ornithologie und Naturschutz Bitterfeld-Wolfen“ und war von 1979 bis 2005 ihr Vorsitzender.